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Abstract
Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with 
few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically 
appropriate as operative intervention is associated with high peri-operative risk. We present an elderly patient with mild 
hypercalcemia secondary to primary hyperparathyroidism. The clinical decision was initially to watch and wait. The patient 
subsequently developed cognitive impairment and was diagnosed with mixed Alzheimer’s disease/vascular dementia. She 
became dependent for all care and housebound. A therapeutic trial of cinacalcet was commenced following a further acute 
rise in serum calcium. Significant reversal of her functional and cognitive deficit occurred. She was no longer fully depend-
ent. Mini mental state examination (MMSE) improved from 8/30 to 21/30. In vulnerable neural systems, even mild elevation 
in serum calcium may have a profound effect on cognition and function. We propose a therapeutic trial of cinacalcet in such 
patients.
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Background
Hypercalcemia is a common biochemical abnormality 
encountered in clinical practice [1, 2]. While important 
causes such as malignancy and myeloma should be excluded, 
in the context of an inappropriately normal or elevated para-
thyroid hormone (PTH) level, a diagnosis of primary hyper-
parathyroidism is made [1]. In people who are otherwise fit, 
operative intervention offers cure [1, 2]. Primary hyperpar-
athyroidism frequently presents in the elderly who are mul-
timorbid and therefore surgical intervention is not possible 
[3]. In these patients, if they are relatively asymptomatic, 
an active surveillance approach is adopted with intermittent 
monitoring of serum calcium [3]. We present a case of a 
patient with mixed dementia, marked cognitive and func-
tional decline, and co-morbid primary hyperparathyroidism. 
The patient was unfit for surgical management. An acute rise 
in serum calcium to 3.23 mmol/L (2.20–2.60 mmol/L) was 
incidentally found on admission bloods following a fall. After 
initial fluid resuscitation, cinacalcet was commenced to pre-
vent further acute serum calcium rises. Unexpectedly, there 
was a significant cognitive and functional improvement over 
a 6-month period following commencement of cinacalcet.
Clinical case
Mrs M. an 87-year-old woman with a background of mixed 
vascular and Alzheimer’s dementia was referred to our ser-
vice while an inpatient following a fall. The patient had a 
past medical history of type 2 diabetes mellitus, osteoporosis, 
hypothyroidism, ischemic heart disease, and primary hyperpar-
athyroidism (pHPT) — under observation at a neighbourhood 
health center.
Mrs M. had biochemical evidence of pHPT for several 
years from her GP records. On initial referral to another 
endocrine service, PTH was 9.9 pmol/L (1.6–6.9 pmol/L) 
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with a corresponding adjusted calcium of 2.99 mmol/L. 
Random urine calcium to creatinine ratio was raised at 
0.71 mmol/mol. Renal function was normal. Vitamin D 
levels were insufficient at 25 nmol/L (> 50 nmol/L) and 
myeloma screen was negative. Mrs M. was independently 
mobile with a stick and had no overt cognitive impairment. 
The patient had asymptomatic hypercalcemia. Vitamin D 
was adequately replaced, and Mrs M. was recommended for 
endocrinological follow-up.
However, in the interim, Mrs M. had a period of cognitive 
decline and worsening mobility with falls. She was referred 
to old age psychiatry. CT brain demonstrated age-related 
cerebral atrophy with small vessel disease. Mini mental state 
examination (MMSE) was 9/30 and functional assessment 
with occupational therapy demonstrated significant func-
tional impairment. Alzheimer’s and vascular mixed demen-
tia was diagnosed. Her cognitive condition worsened, and 
Mrs M. required a full package of care with carers attending 
4 times daily. She became housebound and incontinent.
Mrs. M received acute medical admission to our hospi-
tal following a fall at home. Her calcium was found to be 
3.23 mmol/L. PTH was elevated at 11.4 pmol/L. Vitamin D 
was 55 nmol/L. She was hydrated with IV fluids to urgently 
lower her calcium. Endocrinological guidance was sought 
and cinacalcet 30 mg twice daily was commenced.
Outcome
In the clinic 6 months later, adjusted calcium had fallen 
to 2.30 mmol/L with a corresponding PTH of 4.0 pmol/L. 
There had been a marked improvement in her functional 
status since commencing cinacalcet. Mrs M. was now inde-
pendently dressing and washing, and her daughter reported 
that she was doing her own housework again. Her pack-
age of care had been significantly reduced. Mrs M. was no 
longer incontinent. There had been no further admissions 
with falls. Her family felt that her cognitive state was vastly 
improved. Her daughter reported that she felt her mother 
no longer had any significant appreciable cognitive impair-
ment in day-to-day interaction. No other drugs for dementia 
had been commenced over the intervening period. Repeat 
MMSE was performed with an improvement in her score to 
21/30 from 9/30.
Discussion
Primary hyperparathyroidism is characterized by over 
production of PTH [1, 2, 4]. It is characterized biochemi-
cally by elevated adjusted serum calcium with an inap-
propriately non-suppressed or frankly elevated PTH [2]. 
This leads to increased bone calcium resorption, increased 
intestinal calcium uptake, and augmented tubular resorp-
tion of calcium. Furthermore, PTH acts to increase conver-
sion of vitamin D to its active form [4]. In approximately 
80% of cases, a single underlying benign parathyroid ade-
noma is responsible. In 15%, parathyroid hyperplasia of 
multiple glands is present. The remaining 5% is composed 
of both multiple adenomas and very rarely parathyroid 
carcinoma [2, 4]. In an elderly and frail population with 
multimorbidity, the management of pHPT can be chal-
lenging [1, 5]. Definitive management in the form of par-
athyroidectomy is often curative in the context of a single 
benign parathyroid adenoma with excess PTH secretion 
[1]. Surgical intervention however is often precluded due 
to significant co-morbidity and resultant anesthetic risk 
in older people. In this context and with mild hypercalce-
mia, an approach of active surveillance is often adopted by 
endocrinologists as was the case with this patient [1, 6]. 
This is particularly true when the patient is asymptomatic 
and hypercalcemia is detected only incidentally. This 
is true in up to 80% of cases [1, 2, 5]. When symptoms 
are present, they vary from mild subtle symptomatology 
to more severe symptoms likely to lead to presentation 
for investigation. Urinary frequency and thirst from the 
osmotic effect of high calcium may be present. Patients 
may complain of constipation and abdominal discomfort. 
More severe symptoms associated with nephrolithiasis or 
bone disease may however be the presenting feature. [4]
Hypercalcemia is known to be associated with numerous 
neurocognitive abnormalities ranging from subtle cogni-
tive and mood changes to overt cognitive impairment with 
dementia [5]. Low mood and anxiety may precede more sig-
nificant neurocognitive effects of hypercalcemia. Often this 
presents in a subacute manner over months to years adding 
further diagnostic difficulty. The underlying mechanisms 
leading to the neuropsychiatric features of hypercalcemia are 
however complex and still incompletely understood [2, 4].
Cinacalcet is a calcimimetic agent. It acts on the calcium 
sensing receptor (CasR) through allosteric activation [7]. 
This is a G-protein coupled receptor which is expressed on 
the parathyroid cell surface and in several other tissues. In 
normal physiology, as extracellular calcium levels rise, cal-
cium activates the CasR leading to a cascade of intracellu-
lar actions with the ultimate effect of reducing PTH secre-
tion [8]. Cinacalcet binds to the CasR leading to enhanced 
responsiveness to extracellular calcium. This reduces PTH 
secretion and therefore serum calcium levels. It is low cost 
and well tolerated by most patients. Cinacalcet is effective 
in reducing serum calcium and therefore reducing the symp-
toms associated with this. When used in the long term, it is 
effective at maintaining reasonably stable calcium levels [3, 
7]. In this case, it was only following an acute hypercalce-




While calcium can lead to significant neurocognitive 
impairment alone, it is likely that in the present case, char-
acterized by neural system vulnerability underlying cere-
brovascular disease, Alzheimer’s disease and dementia, that 
elevated serum calcium levels had a disproportionate impact 
on this patient’s neurofunctional status. The impact this sub-
sequently had on both the patient and her extended family 
was profound. Significant social care input was required with 
the attendant resource and financial implications. Although 
there was a significant numerical improvement in MMSE 
after cinacalcet administration, it is the gain in functional 
status that was arguably the most significant benefit to the 
patient and her family.
Conclusion
Significant functional and cognitive impairment can occur with 
elevated serum calcium levels in primary hyperparathyroidism. 
In patients who additionally have vulnerable neural systems 
secondary to advanced age, underlying cerebrovascular dis-
ease, and dementia, this neurological deficit may be more clini-
cally and functionally profound. Given the high tolerability, 
affordability, and ongoing beneficial effects on serum calcium, 
a therapeutic trial of cinacalcet should be considered in people 
presenting with cognitive impairment and elevated serum cal-
cium who are unfit for definitive surgical management.
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